TABLE 1.
Demographic and clinical characteristics at baseline
| Characteristics |
Rivaroxaban 20 mg n = 134 |
Rivaroxaban 10 mg n = 120 |
Aspirin 100 mg n = 108 |
|---|---|---|---|
| Age, y, median (IQR) | 38 (32‐44) | 38 (30‐46) | 39 (32‐45) |
| Weight, n (%) | |||
| ≤70 kg | 64 (47.8) | 54 (45.0) | 57 (52.8) |
| 70 to ≤90 kg | 36 (26.9) | 32 (26.7) | 26 (24.1) |
| >90 kg | 34 (25.4) | 34 (28.3) | 25 (23.1) |
| Body mass index, n (%) | |||
| <30 kg/m2 | 87 (64.9) | 78 (65.0) | 75 (69.4) |
| ≥30 kg/m2 | 47 (35.1) | 42 (35.0) | 33 (30.6) |
| Creatinine clearance, n (%) | |||
| <50 mL/min | |||
| 50 to <80 mL/min | 11 (8.2) | 7 (5.8) | 5 (4.6) |
| ≥80 mL/min | 123 (91.8) | 113 (94.2) | 103 (95.4) |
| Prior anticoagulation, n (%) | |||
| DOACs | 53 (39.5) | 51 (42.5) | 52 (48.1) |
| Heparin/VKA | 69 (50.7) | 57 (47.5) | 48 (44.4) |
| Combinations DOACs/heparin/VKA | 12 (9.0) | 12 (10.0) | 8 (7.4) |
| Hemoglobin, g/dL, median (IQR) | 13.3 (12.4‐14.2) | 13.1 (12.4‐13.8) | 13.3 (12.4‐13.9) |
| Hemoglobin < 12 g/dL, n (%) | 27 (20.1) | 23 (19.2) | 22 (20.4) |
| Iron supplementation, n (%) | 7 (5.2) | 12 (10.0) | 5 (4.6) |
| NSAID use, n (%) | 0 | 1 (8.3) | 0 |
| History of heavy menstrual bleeding, n (%) | 2 (1.5) | 3 (2.5) | 0 |
| Gynecological disorders, n (%) | 3 (2.2) | 5 (4.2) | 7 (6.5) |
Abbreviations: DOACs, direct oral anticoagulants; IQR, interquartile range; NSAID, nonsteroidal anti‐inflammatory drug; VKA, vitamin K antagonist.